1. Academic Validation
  2. Targeting SPP1+ macrophages via the SPP1-CD44 axis reveals a key mechanism of immune suppression and tumor progression in ovarian cancer

Targeting SPP1+ macrophages via the SPP1-CD44 axis reveals a key mechanism of immune suppression and tumor progression in ovarian cancer

  • Int Immunopharmacol. 2025 Jul 28:160:114906. doi: 10.1016/j.intimp.2025.114906.
Lisha Hou 1 Mei Jiang 1 Yue Li 1 Jin Cheng 1 Fei Liu 1 Xiaoyang Han 1 Jiahao Guo 2 Lei Feng 1 Zhefeng Li 1 Junjie Yi 1 Xiaoting Zhao 3 Yan Gao 4 Wentao Yue 5
Affiliations

Affiliations

  • 1 Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, China.
  • 2 Centre for Molecular Medicine Norway, Faculty of Medicine, University of Oslo, Gaustadelléen 21, 0349 Oslo, Norway.
  • 3 Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, China. Electronic address: zhao_xiaoting@ccmu.edu.cn.
  • 4 Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, China. Electronic address: gy19861@126.com.
  • 5 Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, China. Electronic address: yuewt@ccmu.edu.cn.
Abstract

Tumor-associated macrophages (TAMs) play a pivotal role in immune suppression, tumor progression, and metastasis within the tumor microenvironment (TME) of ovarian Cancer. While TAMs are known to promote T-cell dysfunction, the precise molecular mechanisms governing this process remain poorly understood. Here, we performed an integrated analysis of six high-grade serous ovarian Cancer (HGSOC) single-cell Sequencing datasets to investigate the molecular and functional diversity of TAMs in HGSOC. We identified an SPP1+ TAM subpopulation enriched in HGSOC and strongly associated with poor prognosis. These macrophages promoted T-cell exhaustion via the SPP1-CD44 axis, which emerged as the principal mediator of immune suppression. Functional assays demonstrated that SPP1 secreted by TAMs drove T-cell exhaustion, weakening anti-tumor immunity. Blocking either SPP1 or CD44 effectively reversed T-cell exhaustion, restored CD8+ T-cell functionality, and suppressed tumor growth in vivo. Furthermore, molecular docking and dynamics simulations identified nilotinib as a potential SPP1 inhibitor, exhibiting strong binding affinity and stability. In vitro assays confirmed that nilotinib reduced PD-1 expression in Jurkat cells induced by M2-type macrophages, underscoring its therapeutic potential in reversing T-cell exhaustion in ovarian Cancer. The research demonstrates that SPP1+ TAMs drive immune suppression and T-cell exhaustion in ovarian Cancer via the SPP1-CD44 axis, highlighting this pathway as a promising therapeutic target for reprogramming the immune microenvironment and improving patient outcomes.

Keywords

CD8(+) T-cell exhaustion; Immunosuppression; Ovarian cancer; SPP1(+) TAMs; Single-cell analysis.

Figures
Products
Inhibitors & Agonists
Other Products